Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis

Summary

The hypothesis of the study is that according to modern data, the pathogenesis of multiple sclerosis is inextricably linked to the patient's microbiota. Therefore, transplantation of a normal fecal microbiota (FMT) can improve the outcome of autologous hematopoietic stem cell transplantation (autoHSCT) by increasing the disease-free period and disease progression suspension for at least 5 years after transplantation, which meets the NEDA (No Evidence of Disease Activity) criteria, satisfying the current trends of clinical neurology.

Timeline

Start

2019-06-01

Primary completion

2023-11-29

Completion

2023-11-29

Drugs

Indications